U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Substance Class Protein
Created
by admin
on Sat Dec 16 12:08:26 GMT 2023
Edited
by admin
on Sat Dec 16 12:08:26 GMT 2023
Protein Type RECEPTOR
Protein Sub Type ACETYLCHOLINE RECEPTOR
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
P4J1I8C6CX
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NEURONAL ACETYLCHOLINE RECEPTOR SUBUNIT ALPHA-7
Common Name English
ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR
Common Name English
NEURONAL ACETYLCHOLINE RECEPTOR ALPHA-7
Common Name English
NACHRA7
Common Name English
.ALPHA.7 NICOTINIC ACETYLCHOLINE RECEPTOR
Common Name English
α7 nAChR
Common Name English
Code System Code Type Description
FDA UNII
P4J1I8C6CX
Created by admin on Sat Dec 16 12:08:29 GMT 2023 , Edited by admin on Sat Dec 16 12:08:29 GMT 2023
PRIMARY
UNIPROT
P36544
Created by admin on Sat Dec 16 12:08:29 GMT 2023 , Edited by admin on Sat Dec 16 12:08:29 GMT 2023
PRIMARY
From To
1_128 1_142
1_190 1_191
2_128 2_142
3_128 3_142
4_128 4_142
5_128 5_449
Glycosylation Type HUMAN
Glycosylation Link Type Site
N 1_24
N 1_68
N 1_111
N 2_24
N 2_68
N 2_111
N 3_24
N 3_68
N 3_111
N 4_24
N 4_68
N 4_111
N 5_24
N 5_68
N 5_111
Related Record Type Details
INHIBITOR -> TARGET
ALZHEIMERS DISEASE DRUG ANTAGONIZING NMDA RECEPTOR, ANTAGONISM OF .ALPHA.7 NACHR IS A SIDE PATHWAY.
PARTIAL AGONIST->TARGET
ACTS AS PARTIAL AGONIST; ACTIVATES ERK1/2 AND CREB PHOSPHORYLATION; ENHANCES COGNITIVE PERFORMANCE. ; ALPHA 7 IN VITRO DATA: Ki = 10.8 nM
AGONIST -> TARGET
RADIOLIGAND->TARGET
AGONIST -> TARGET
GTS-21 was able to improve survival rate of BALB/c mice suffered from endotoxemia when applied in dose 4 mg/kg. As proved on a C57BL6 mouse model, the compound is also suitable for prevention of inflammatory injury induced by mechanical ventilation. In addition to the anti-inflammatory pathway, GTS-21 was assessed in a clinical trial and was proved to improve the cognitive functions of schizophrenic patients.
RADIOLIGAND->TARGET
AGONIST -> TARGET
ALPHA 7 IN VITRO DATA: Ki = 27 +/- 0.9 nM
AGONIST -> TARGET
AGONIST -> TARGET
PNU-282,987: A SELECTIVE AND POTENT AGONIST, BUT MAY CAUSE LONG QT SYNDROME.
AGONIST -> TARGET
ANABASINE IS A PYRIDINE AND PIPERIDINE ALKALOID FOUND IN THE TREE TOBACCO (NICOTIANA GLAUCA) PLANT, A CLOSE RELATIVE OF THE COMMON TOBACCO PLANT (NICOTIANA TABACUM). IT IS A STRUCTURAL ISOMER OF, AND CHEMICALLY SIMILAR TO, NICOTINE. ITS PRINCIPAL (HISTORICAL) INDUSTRIAL USE IS AS AN INSECTICIDE. ANABASINE IS PRESENT IN TRACE AMOUNTS IN TOBACCO SMOKE, AND CAN BE USED AS AN INDICATOR OF A PERSON'S EXPOSURE TO TOBACCO SMOKE.
AGONIST -> TARGET
RADIOLIGAND->TARGET
AGONIST -> TARGET
AGONIST
STRONG
AGONIST -> TARGET
Promising compounds acting as a α7 nAChR selective agonists seem to be also AZD0328 and TC-5619, both containing azabicyclooctane group. They are expected to be useful to treating multiple cognitive dysfunctions and schizophrenia .
AGONIST -> TARGET
PHA-543,613: A SELECTIVE AND POTENT AGONIST WITH NOOTROPIC PROPERTIES.
AGONIST -> TARGET
NICOTINE IS AN ANTIHERBIVORY ALKALOID AND POTENT PARASYMPATHOMIMETIC STIMULANT AND FOUND IN PLANTS, MOSTLY THOSE IN THE NIGHTSHADE FAMILY. NICOTINE ACTS AS A RECEPTOR AGONIST AT MOST NICOTINIC ACETYLCHOLINE RECEPTORS (NACHRS), EXCEPT AT TWO NICOTINIC RECEPTOR SUBUNITS (NACHR.ALPHA.9 AND NACHR.ALPHA.10) WHERE IT ACTS AS A RECEPTOR ANTAGONIST.
AGONIST -> TARGET
CNI-1493 was found to be effective for resolving of endotoxic shock in a rat model. In a clinical trial, CNI-1493 was examined as a drug for the treatment of Crohn’s disease, a disease associated with inflammation. The investigators reported no plausible effect for CNI-1493 single and 3 day dosing. However, cumulative dosing brings some positive effects to Crohn’s disease therapy.
AGONIST -> TARGET
AGONIST -> TARGET
AGONIST -> TARGET
AR-R17779 IS A DRUG THAT ACTS AS A POTENT AND SELECTIVE FULL AGONIST FOR THE .ALPHA.7 SUBTYPE OF NEURAL NICOTINIC ACETYLCHOLINE RECEPTORS. IT HAS NOOTROPIC EFFECTS IN ANIMAL STUDIES, BUT ITS EFFECTS DO NOT SUBSTITUTE FOR THOSE OF NICOTINE. IT HAS ALSO RECENTLY BEEN STUDIED AS A POTENTIAL NOVEL TREATMENT FOR ARTHRITIS.
AGONIST -> TARGET
(.ALPHA.7 NACHR) IN VITRO DATA KI = 13.5 NM
AGONIST -> TARGET
(.ALPHA.7 NACHR) IN VITRO DATA KI = 6 NM (R)
AGONIST -> TARGET
WAY-317538 (SEN-12333) IS A DRUG THAT ACTS AS A POTENT AND SELECTIVE FULL AGONIST FOR THE .ALPHA.7 SUBTYPE OF NEURAL NICOTINIC ACETYLCHOLINE RECEPTORS.
AGONIST -> TARGET
NEGATIVE ALLOSTERIC MODULATOR (NAM)->TARGET
AGONIST -> TARGET
TROPISETRON ACTS AS BOTH A SELECTIVE 5-HT3 RECEPTOR ANTAGONIST AND .ALPHA.7-NICOTINIC RECEPTOR AGONIST.
INHIBITOR -> TARGET
NEGATIVE ALLOSTERIC MODULATOR
ALLOSTERIC
RADIOLIGAND->TARGET
Ki
AGONIST -> TARGET
ACETYLCHOLINE (ACH) IS AN ORGANIC CHEMICAL THAT FUNCTIONS IN THE BRAIN AND BODY OF MANY TYPES OF ANIMALS, INCLUDING HUMANS, AS A NEUROTRANSMITTERA CHEMICAL MESSAGE RELEASED BY NERVE CELLS TO SEND SIGNALS TO OTHER CELLS (NEURONS, MUSCLE CELLS, AND GLAND CELLS).
AGONIST -> TARGET
(.ALPHA.7 NACHR) IN VITRO DATA KI = 8.8 +/- 1.3 NM
AGONIST -> TARGET
ALPHA 7 IN VITRO DATA: INCREASES MAX AGONIST RESPONSE 17 TO 20-FOLD.
AGONIST -> TARGET
PARTIAL AGONIST->TARGET
RADIOLIGAND->TARGET
AGONIST -> TARGET
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT CHEMICAL
Molecular Formula CHEMICAL